ANKARA — South Korean biopharmaceutical company SK Plasma has signed a technology transfer and licensing agreement worth approximately $75 million with Proturk, a joint initiative supported by the Turkish Red Crescent. The partnership aims to advance the production of plasma-derived medicines in Türkiye.
According to the company, the deal represents the largest technology export contract since SK Plasma was established in 2015.
Technology Transfer and Equity Stake
Under the agreement, SK Plasma will provide licenses, research and development capabilities, and production technologies necessary for manufacturing plasma-derived medicines at a new facility planned in Türkiye.
In addition, SK Plasma will acquire a 15% stake in Proturk for €150,000, allowing the company to earn dividend income depending on the venture’s future performance.
Production Facility Planned in Ankara
As part of the technology transfer process, SK Plasma will share operational expertise from its plasma fractionation facility in Andong, where the company has developed significant experience in plasma processing.
The new manufacturing facility is planned for Çubuk, a district of Ankara. Once completed, the plant will enable local production of critical plasma-based medicines such as albumin and immunoglobulin, which have largely been supplied through imports until now.
Strengthening Health Security
SK Plasma CEO Kim Seung-joo said the project goes beyond a simple technology export.
According to Kim, the company plans to transfer its full operational system to the local facility, strengthening cooperation with Türkiye while improving access to essential medicines and enhancing the country’s healthcare security.
The initiative is seen as a key step in Türkiye’s strategy to establish domestic plasma fractionation capacity, reducing reliance on imported plasma-based pharmaceuticals.
Source: Patronlar Dünyası/ Prepared by: İlayda Gök